Final survival analysis shows significant boost with enzalutamide in mHSPC
May 2nd 2022The final results from the phase 3 ARCHES trial showed that the addition of enzalutamide to androgen deprivation therapy also continued to improve radiologic progression-free survival and other secondary end points.